Proactive - Interviews for investors

Glycotest CEO discusses University of Georgia partnership for early liver cancer detection

Charles Swindell, the CEO of Glycotest, a EMV Capital portfolio company, talked with Proactive's Stephen Gunnion about the company’s progress in liver disease diagnostics, specifically its new partnership with the University of Georgia’s Complex Carbohydrate Research Center (CCRC).

Swindell highlighted Glycotest’s focus on detecting early-stage liver cancer using their HCC Panel blood test, which aims to address current limitations in liver cancer diagnostics that often miss early-stage cases. "Our flagship test is the HCC Panel for curable early-stage liver cancer," Swindell noted, explaining how the test could detect cases missed by standard tests.

Swindell emphasised the partnership with the University of Georgia CCRC as essential for finalising the commercial platform, which will use the expertise of CCRC in carbohydrate-derived biomarkers for liver disease. With 3.1 million potential test candidates in the US alone and an additional 380 million globally, the market opportunity is vast.

"We believe that we are well differentiated from competitors," he added, pointing to the unique biomarkers Glycotest employs.

To hear more about Glycotest’s plans for commercialization and how its technology could impact liver disease diagnosis, watch the full interview. Visit Proactive’s YouTube channel for more updates, and don’t forget to like, subscribe, and turn on notifications for our latest videos.

#Glycotest #LiverCancer #LiverDisease #CancerDiagnostics #CharlesSwindell #HCCPanel #ProactiveInvestors #MedicalInnovation #UGAPartnership #BiomarkerResearch #HealthTech #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Broadcast on:: 07 Oct 2024
Audio Format:: other

Hello, you're watching Proact, and I'm joined by Charles Swindell. He's the CEO of Glycoteast, an EMV capital portfolio company. Charles, it's very good to meet you. Congratulations on your recent agreement with University of Georgia. Before we get into the details, can you give us a quick overview of what Glycoteast test does and how you're working to end liver cancer. So first of all, Stephen, thank you very much for the opportunity to share recent developments at Glycoteast. So Glycoteast is a liver disease diagnostics company. We're focused on liver cancers and liver fibrosis. Our flagship test is the ACC panel for curable early stage liver cancer. The point is that liver cancer can be cured if caught early, but correct standard of care tests leave approximately 40% of patients with early stage disease undetected. This is the problem we aim to solve with the ACC panel. We have a world-leading biobank of serum samples from liver disease patients. We have licensed our technology in China for the huge Chinese liver disease population. And we are working to commercialize in the US. Lastly, we are in the capital portfolio company, and we are very grateful for the continuing support we receive from EMB. That's a very exciting development, Charles. Can you give us some background as to why the University of Georgia partnership is such a significant step forward for the company? Sure. So we are delighted to be partnered with the University of Georgia complex carbohydrate research center or CCRC. They are a world leader in Black Science R&D. And this is highly relevant to our technology, which is based on carbohydrate-derived biomarkers. Just to provide a little background, we have completed our clinical validation study enrollment for the HCC panel. And our work with the CCRC should enable us to finalize the commercial platform for this important test. This is a major step toward market launch of the HCC panel. Charles, in terms of commercialization, how big is the market? So the market is huge. The market for our test worldwide is worth multi billions of dollars. We estimate that the target patient population for our HCC panel test in the U.S. is 3.1 million outside the U.S., where internationally it's up to 380 million patients who would be eligible for a test of this sort. What distinguishes Black Test in this space is the technology that we are based on. So our biomarkers and biomarker panels and assays exploit unique carbohydrate-derived disease signals. So we believe that we are well-differentiated from competitors in this space. So what's next for Glaco tests and other disagreements in place, Charles? So we expect our work with the University of G of Georgia CCRC to be the final chapter in making the HCC panel test available commercially. We believe the HCC panel can become a very important tool for the detection of curable early stage. Liver cancer, put the benefit of the patients or risk and for the physicians who care for them. This is what we're really excited about at Glaco tests. Charles, I hope you keep us updated on any progress. Thank you very much for speaking with us today. Thank you, Charles. When does the CEO of Glaco test? [MUSIC PLAYING]